Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

Sponsor
Oman Ministry of Health
Study ID
NCT07491042
Status
Recruiting
Apply to this trial

Conditions

  • End Stage Chronic Renal Failure

Eligibility Criteria

Sex
ALL
Age
13 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    study the effect of selective SGLT2i Dapagliflozin on peritoneal dialysis patients regarding UF/Kt/v and residual renal function

Study Details

This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation. The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.

Key Dates

Start date
Apr 1, 2026
Status verified
Mar 2026
Primary completion
Sep 30, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
38 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: selective SGLT2i Dapagliflozin and peritoneal dialysis
    it is clinical trial on drug Dapagliflozin and its effect on peritoneal dialysis: UF, Kt/V, and residual renal function, No of patients is 38

Primary Outcome Measure

change in ultrafiltration volume in liter [ Time Frame: 3 months ]

Central Contacts

Related Studies